Endo, Inc. (OTCQX: NDOI) announced today that data related to the use of XIAFLEX® (collagenase clostridium histolyticum, or CCH) for the treatment ...

Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed merger of Endo, Inc. (OTC: NDOI) and Mallinckrodt plc. Under the terms of the proposed transaction, ...

Pharmaceutical leaders Mallinckrodt plc and Endo, Inc. (OTCQX: NDOI) have entered an agreement to merge, creating a global, diversified company poised to deliver enhanced patient ...

will combine their branded drugs businesses that include Endo's testosterone injection Aveed as well as Mallinckrodt's Acthar Gel and kidney disease therapy Terlivaz. Advt The merger will "create ...

Malvern-based Endo has agreed to merge with Mallinckrodt in a cash and stock deal ... Read more about Endo locking into a merger agreement in the Philadelphia Business Journal.

Mallinckrodt, the Irish pharmaceutical company with its U.S. headquarters in Hazelwood, has agreed to merge with drug maker ...

Wachtell Lipton Rosen & Katz and Davis Polk & Wardwell have scored lead roles on the $6.7bn merger of drugmakers Mallinckrodt and Endo. Wachtell is serving as lead counsel for Dublin-based ...

In addition, Endo has entered into an agreement to sell the international pharmaceutical business to Knight Therapeutics Inc. for $99 million. The deal will reduce costs and expand access to new ...